Fatty liver disease (MASLD) - Symptoms and causes - Mayo Clinic
Dec 12, 2025 · Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (NAFLD), is a liver condition that affects people with excess …
Fatty liver disease (MASLD) - Diagnosis and treatment - Mayo Clinic
Zahoor F, et al. Association of metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease with Type 2 diabetes mellitus: A case-control study in a tertiary …
非酒精性脂肪性肝病 - 症状与病因 - 妙佑医疗国际
Oct 15, 2025 · 非酒精性脂肪性肝病常被简称为 NAFLD，是一种累及很少喝酒或完全不喝酒的人的肝脏问题。 NAFLD 患者的肝脏中积聚过多脂肪。 这种状况最常见于超重或肥胖症患者。 随 …
Enfermedad hepática del hígado graso no alcohólico
Oct 15, 2025 · La enfermedad hepática esteatósica asociada a disfunción metabólica, antes conocida como enfermedad del hígado graso no alcohólico, es una afección hepática que …
Fatty liver disease (MASLD) care at Mayo Clinic
Dec 12, 2025 · Harmeet Malhi, M.B.B.S., Gastroenterology & Hepatology, Mayo Clinic: NAFLD stands for nonalcoholic fatty liver disease. It really is an umbrella term for a continuum of …
Groundbreaking discovery links inherited mutation to fatty liver ...
Apr 22, 2025 · Video: A healthy liver transitions to cirrhosis, illustrating a potential outcome of metabolic dysfunction-associated steatotic liver disease — formerly known as nonalcoholic …
Fatty liver disease (MASLD) - Stages - Mayo Clinic
Dec 12, 2025 · Zahoor F, et al. Association of metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease with Type 2 diabetes mellitus: A case-control study in …
非酒精性脂肪性肝病 - 在 Mayo Clinic 治疗 - 妙佑医疗国际
Oct 15, 2025 · 由于采用了新型肝脏成像技术，许多在妙佑医疗国际就诊的可能患有 NAFLD 和 NASH 的患者可避免肝脏活检。 妙佑医疗国际的研究人员研发了一种非侵入性技术，即磁共振 …
Fatty liver disease (MASLD) - Doctors and departments - Mayo Clinic
Dec 12, 2025 · This liver condition is becoming more common in the Western world. Find out how to treat and prevent this potentially dangerous liver disease.
NAFLD and NASH research update - Mayo Clinic
Feb 20, 2018 · Mayo Clinic researchers are exploring several new treatment options for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).